This prospective study included 68,759 Chinese male adults from Kailuan cohort of China who had a standardized medical examination between 2006 and 2007 and were followed up for approximately 8 years until occurrence of ASCVD, cancer or death or until December 31, 2014. Subjects were divided into four categories based on the quartiles of TC, LDL-C and non-HDL-C. Cox regression models were used to estimate hazard ratios (HRs) and their 95% confidence intervals (CIs). During follow-up, 2,916 males developed ASCVD and 1,884 developed cancer. Compared with the lowest quartile, the upper-most quartiles of TC, LDL-C and non-HDL-C were all associated with increased ASCVD risk (HR 1.53; HR 1.16; HR 1.55); however, the upper-most quartiles of TC, LDL-C and non-HDL-C were all negatively associated with cancer (HR0.84; HR 0.82; HR 0.80) and these associations were present after exclusion of incident cancers during the first 4 years of follow-up. In a word, we report that high TC, LDL-C and non-HDL-C concentrations increased ASCVD incidence in a male population and that these lipid profiles were inversely associated with total cancer and several individual cancers.
Cardiovascular disease and cancer are the most common diseases and are responsible for the highest mortality worldwide. With the development of the field of cardio-oncology, it is important to reveal shared risk factors by cardiovascular disease and cancer. Dyslipidemia such as high total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are considered as a risk factor of atherosclerotic cardiovascular disease (ASCVD), 1, 2 but their association with cancer remains unclear. Non-high-density lipoprotein cholesterol (non-HDL-C or HDL-C subtracted from TC) is used for estimating the total amount of atherogenic lipoproteins including very lowdensity lipoprotein (VLDL), VLDL remnants, intermediate density lipoprotein (IDL), LDL, and lipoprotein (a). Recently, non-HDL-C was demonstrated to be a better risk indicator for cardiovascular events compared to LDL-C. 3 In addition, very few studies have been performed to explore the association between non-HDL-C and cancer.
Since the 1980s, the relationship between TC and cancer has been investigated. 4 In addition to the roles in cellular structure and function, cholesterol is a precursor of several steroid hormones such as estrogen and androgen, and can synthesize bile acids in the liver. Thus, cholesterol was thought to be involved in the etiology of certain cancers including breast cancer, prostate cancer and colorectal cancer. 30 However, several of these findings were inconsistent and have been controversial. A number of epidemiologic studies have identified the inverse association between cholesterol and cancer incidence, [5] [6] [7] [8] [9] [10] but several have shown this to be potentially linked to the preclinical effect of cancer. Thus, a mechanism of cancer-induced changes in cholesterol may be formed. In malignant cells, cholesterol catabolism increased, 11 and a higher consumption of cholesterol for new cellular membrane biogenesis in cancer tissues. However, the preclinical effects of cancer cannot entirely explain this association because the inverse association between cholesterol and cancer was still present after excluding incident cancers during the first several years of follow-up. 5 Studies researching the associations between lipid profiles, especially LDL-C, and non-HDL-C with cancer have been limited.
In this study, we explored the association between TC, LDL-C, and non-HDL-C with ASCVD or cancer incidence in a Chinese male population over approximately an 8-year follow-up period.
Methods

Selection of study population
This was a prospective study on a Chinese male population derived from the Kailuan Cohort Study, which included a large number of employees and retirees of the Kailuan company, a coal mining company located in in Tangshan, Hebei Province of China, with eleven affiliated hospitals. 12 From 2006 to 2007, a total of 101,510 subjects (81,110 males and 20,400 females) of the Kailuan Company underwent physical examination and laboratory testing at the eleven hospitals. From then on, these subjects had a biennial medical examination. The study was performed according to the guidelines of the Helsinki Declaration, and was approved by the Ethics Committee of Kailuan General hospital. All participants had signed informed consent forms.
In our study, we included the 81,110 males who had physical examination at baseline between 2006 and 2007. Participants who had at least one of the following were excluded: (i) a history of cardiovascular disease (include myocardial infarction and stroke) (2734); (ii) a history of cancer (262), (iii) missing history of cardiovascular disease or cancer (3094); (iv) having no ASCVD or cancer and being dead during follow-up (4083); (v) missing information of lipid profiles in the first examination (1406); and (vi) use of lipid-lowing agents (772). After the application of exclusion criteria, 68,759 male subjects aged 18 years or older were registered in this study.
Data collection and assessment of variables
The participants underwent standardized biennial examinations, including physical examination and laboratory testing, at designated local hospitals. Standard procedures for the examinations have been previously detailed. 13, 14 Information on demographic, socioeconomic and other variables were obtained via standardized questionnaires at the baseline interview between 2006 and 2007, including age, gender, education, income, marital status, physical activity, cigarette smoking, alcohol consumption and medical history. Hypertension was defined by the presence of a history of hypertension, using antihypertensive agents, systolic blood pressure 140 mm Hg or diastolic pressure 90 mm Hg. Blood pressure was measured at least two times at rest. Diabetes mellitus was defined by the presence of a history of diabetes mellitus, using insulin or oral hypoglycemic agents or fasting blood glucose (FBG) level 7.0 mmol/L. Body weight and height were measured with participants wearing light clothing.
Blood samples were obtained from participants at the fasting state in the morning and stored in vacutainer tubes containing ethylene diamine tetraacetic acid (EDTA). Lipid profiles were measured enzymatically (Mind Bioengineering Co. Ltd, Shanghai, China). FBG was measured with the hexokinase/glucose-6-phosphate dehydrogenase method.
Follow-up and ASCVD/cancer ascertainment
We followed up each participant starting with physical examination at baseline and ending on the date of the diagnosis of ASCVD, cancer or death until December 31, 2014. We updated their health status every year through the information of medical insurance and searching for the hospital records or death confirmed by death certificates. All cancer or ASCVD events were coded using ICD-10 system.
Statistical analysis
TC, LDL-C and non-HDL-C were divided into four categories according to the quartiles. Continuous variables were described by mean 6 standard deviation (SD) and compared using one-way ANOVA analysis. Categorical variables were described by percentages and compared via Chi-Squared tests. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for ASCVD and cancer incidence according to TC, LDL-C and non-HDL-C levels, adjusting for suspected confounders including age, cigarette smoking (defined as never or former smoker and current smoker), alcohol consumption (defined as never or former drinker and current drinker), physical activity (never or ever), hypertension (yes or no), diabetes mellitus (yes or no) and BMI (calculated as weight in kilograms divided by the square of the body height in What's new? High cholesterol is a major risk factor for cardiovascular disease, a leading cause of death worldwide. Cardiovascular disease is potentially associated with cancer, yet despite the common occurrence of both conditions, little is known about their relationship. In this prospective study of more than 68,700 Chinese men, high total cholesterol (TC), high low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) concentrations were linked to increased incidence of cardiovascular disease but not cancer. Moreover, the upper-most quartiles of TC, LDL-C and non-HDL-C levels were negatively correlated with total cancer risk and risk of individual cancers, suggesting an inverse association. meters). To check for reverse causation, we further excluded the participations who were diagnosed with cancer within the first 4 years of follow-up. Spline functions for cox regression modeling were used to show continuous HRs for ASCVD or cancer based on the TC, LDL-C or non-HDL-C levels.
Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, North Carolina, USA), SPSS 13.0 (SPSS Inc, Chicago, IL) and R software. p < 0.05 (two-tailed) was considered statistically significant.
Results
The mean age of the 68,759 male participants was 51.05 years old. The demographic and clinical characteristics of the participants at baseline are shown in Table 1 . We divided the subjects into four groups according to the quartiles of TC, LDL-C and non-HDL-C. Compared with lower levels of TC or non-HDL at baseline, participants with higher levels were typically older and more likely to have hypertension or diabetes mellitus, to currently have cigarette smoking or alcohol consumption and a higher BMI. The characteristics of the participants according to the LDL-C grouping were similar to those of TC or non-HDL-C except age. Compared with higher LDL-C levels at baseline, participants with the lowest levels were typically older (Table 1) .
During a follow-up period of 8 years (ASCVD: 7.82 years; cancer: 7.89 years), 2,916 males (4.2%) were diagnosed with ASCVD, including 2,111 having an ischemic stroke and 868 having a myocardial infarction. 1,884 males (2.7%) were diagnosed with a primary cancer, including 547 having lung cancer, 205 liver cancer, 222 colorectal cancer, 148 stomach cancer, 207 urinary system cancer, 101 pharyngolaryngeal cancer, 91 lymphoma and leukemia, and 363 with other forms of cancer. The incidence of ASCVD or cancer according to the TC/LDL-C/non-HDL-C quartile is shown in Figure 1 . Table 2 presents the unadjusted and multivariable hazard ratios for ASCVD and total cancer incidence. In the multivariate analysis, compared with the first quartiles of TC (<4.31 mmol/L), LDL-C (<1.89 mmol/L) and non-HDL-C (<2.82 mmol/L), the upper-most quartiles of TC (5.60 mmol/L), LDL-C (2.86 mmol/L) and non-HDL-C (4.05 mmol/L) increased the risk of ASCVD 53%, 16% and 55%, respectively. However, multivariate analyses revealed that the upper-most quartiles of TC, LDL-C and non-HDL-C decreased risk of cancer occurrence by 16%, 18% and 20%, respectively. To explore the preclinical effect of cancer on lipid profiles, we further excluded the participations who were diagnosed with cancer in the first 4 years of follow-up. TC, LDL-C and non-HDL-C were still inversely associated with cancer occurrence (Table 4 ; HR 0.79; HR 0.81; HR 0.77). Taken together, we conclude that the higher levels of TC, LDL-C and non-HDL-C are positively associated with increased risk of ASCVD and inversely associated with total cancer.
In a subgroup analysis of several individual cancers (Table  3) , TC had a strong inverse association with liver cancer (HR, 0.26, 95% CI 0.16-0.41) and stomach cancer (HR, 0.63, 95%CI 0.41-0.98). Non-HDL-C was also inversely associated with liver cancer (HR 0.27, 95% CI 0.18-0.43) and stomach cancer (0.53, 95% CI 0.34-0.83). Although LDL-C had no significant association with every individual cancer, it was negatively associated with colorectal cancer as a continuous variable (HR per 1 mmol/L, 0.84, 95% CI 0.72-0.98) and liver cancer (HR per 1 mmol/L, 0.85, 95% CI 0.72-1.00), which are not shown. After we excluded the participations who were diagnosed with cancer in the first 4 years of follow-up (Table 4) , TC remained negatively associated with liver cancer but not with stomach cancer, and non-HDL-C was still negatively associated with liver cancer and stomach cancer. Moreover, after we excluded liver cancer, LDL-C was still significantly negatively associated with cancer (HR 0.83, 95% CI 0.72-0.95,) (data not shown).
Spline functions
Hazard ratio curves for TC, LDL-C and non-HDL-C levels associated with ASCVD and cancer are shown in Supporting Information, Figure 1 . TC, LDL-C and non-HDL-C were associated with ASCVD and cancer in a linear-similar manner except LDL-C in ASCVD.
Discussion
This large, prospective study on a Chinese male population suggested that lipid profiles have different associations with ASCVD and cancer. High levels of TC, LDL-C and non-HDL-C were associated with increased ASCVD incidence, and these lipid profiles were negatively correlated with the risk of total cancer and several individual cancers. We made the above conclusion after adjustment for shared common risk factors by cardiovascular diseases and cancer including obesity, diabetes mellitus, hypertension, hyperlipidemia, tobacco, alcohol and decreased daily physical activity. 15 
TC, LDL-C and non-HDL-C in ASCVD
Dyslipidemia such as high TC and LDL-C are considered risk factors of atherosclerosis and cardiovascular diseases including coronary artery disease and stroke. 16, 17 In fact, LDL-C and non-HDL-C are the main contributors of TC and they have similar effects on ASCVD. Atherogenesis begins when excess lipoproteins such as LDL accumulate in the subendothelial space, are oxidatively modified, and are taken up selectively by macrophages and monocytes. 15 Many studies have confirmed LDL-C as an important risk factor of ASCVD, and have strengthened the benefits of lower LDL-C for ASCVD. 18, 19 Recently, non-HDL-C has been believed as a better risk indicator than LDL-C. 3 Non-HDL-C includes the atherogenic TG-rich lipoproteins, which are essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization, [20] [21] [22] thus supporting the notion of TGs and remnant particles as causative factors in atherogenesis. In our study, we not only confirm that TC and LDL-C were associated with ASCVD Cancer Epidemiology Table 1 . Demographic and baseline characteristics of the study population Lipid ASCVD, Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol.
incidence, but also observed that non-HDL-C increased ASCVD risk.
TC, LDL-C and non-HDL-C in cancer
Previously, several population-based prospective studies have reported the associations between TC and total cancer or several individual cancers in male populations, 5-10 which were partially consistent with our results. However, it remains inconclusive whether the inverse association between cholesterol and cancer is the cause or the effect of preclinical cancer. Malignant cancers can change cholesterol metabolism or absorption, and tumor cells often express receptors that attract cholesterol metabolites to support their growth, consequently resulting in a decrease in the circulating levels of cholesterol. 11 Several clinical trials observed that the levels of circulating cholesterol were reduced 5 years before cancerlinked death 23 and two years before cancer diagnosis. 24 However, this preclinical effect does not entirely explain this association because this inverse association still existed in the lag time analysis (i.e., excluding incident cancers in the first several years of follow-up) as revealed in a large prospective study in Korea. 5 In addition, consistent with previous studies, [5] [6] [7] 9 we found that there was an inverse association between TC and total cancer, particularly between TC and Cancer Epidemiology Table 3 . All models were adjusted for age, cigarette smoking, alcohol consumption, physical activity, hypertension, diabetes mellitus and BMI at baseline.
liver cancer in the males, which was expected because liver cancer may inhibit cholesterol metabolism, and exaggerate the inverse association between cholesterol and liver cancer or all-site cancer. However, Ahn et al. showed that the inverse association between TC and total cancer or liver cancer was not significant after they excluded incident cancers in the first nine years. 9 Additionally, Iso et al. found that the inverse association between TC and liver cancer was strong but the association between TC with total cancer incidence was nonexistent after exclusion of the incident cases in the first 3 years and advanced cancers. 7 To minimize the effect of preclinical cancer, we excluded incident cancers in the first 4 years of follow-up, but still observed inverse associations between TC, LDL-C, non-HDL-C and cancer. We also adjusted for the potential confounding factors including age, cigarette smoking, alcohol consumption, physical activity, hypertension, diabetes mellitus and BMI.
Previously, low cholesterol was proposed to be associated with insufficient immune function or upregulated activity or responsiveness of the mevalonate pathway to influence cancer incidence. 25 In addition, the increased activity of NF-jB nuclear transcription factor by low cholesterol 26 may lead to cell proliferation and increase the risk of cancer. 27 However, we did not further analyze the relationship between cholesterol and cancer with different stages due to lack of related information.
Previous prospective studies also found the presence 5, 7 or absence 6, 9 of an inverse association between TC and stomach cancer. For example, Iso et al. suggested that an inverse association between TC and stomach cancer was not significant after exclusion of incident cancers in the first 3 years and in advanced cases, 7 which was consistent with our observations. However, the inverse association between non-HDL-C and stomach cancer still existed. In addition, Kitahara et al. found a positive link of TC to colorectal and prostate cancers in a male population. The exact mechanisms underpinning these associations remain unclear; however, one mechanism might be involving the utilization of cholesterol to synthesize bile acids and androgen, 28 as high levels of bile acids were linked to increased colorectal cancer incidence 29 and androgen levels were associated with prostate cancer. 28 However, in this study, we found no correlation between TC and colorectal cancer, consistent with other reports. 6, 7, 9 In fact, the relationship between cholesterol and prostate cancer has also been controversial. A recent meta-analysis showed that hypercholesterolemia had no association with prostate cancer. 30 In this study, we did not analyze the association between cholesterol and prostate cancer due to a limited number of prostate cancer cases.
The clear majority of previous epidemiological studies were mainly focused on the correlation between TC and cancer, and few studies have been performed on the association between sub-fractions of cholesterol such as HDL-C, LDL-C or non-HDL-C and cancer. A meta-analysis that included 15 randomized controlled trials suggested that on-treatment LDL-C was negatively associated with cancer. 31 However, 
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another study did not find a significant relationship between LDL-C and cancer. 8 Our prospective study suggests a strong inverse correlation between LDL-C and cancer incidence, even after cases of liver cancer were excluded. The reasons underlying these discrepant findings are not clear. Probably the competing risk may be one mechanism because patients with high cholesterol concentrations were more likely to be censored in some studies due to the fact that cardiovascular death may occur before cancer was diagnosed. More studies with large sample sizes are needed to corroborate these associations including those for cholesterol subfractions such as HDL-C, ApoA1 or ApoB with all site or site-specific cancers.
Some limitations of our study should be noted. First, given that the use of lipid-lowering agents might have effects on cholesterol levels and cancer, we excluded those subjects who used lipid-lowering agents at baseline. However, we lacked information on the use of lipid-lowing agents such as statins during the follow-up period, which might have influenced cancer development through certain mechanisms. 32, 33 In addition, behavioral aspects like dietary habits may have effects on cholesterol levels and cancer. Also, we do not have detailed information about tumor stages and genotype information about apolipoprotein E, which otherwise could help to further confirm the association between cholesterol and cancer. For instance, two reports indicated that low levels of cholesterol were not causally associated with increased cancer risk by using apolipoprotein genotype in Mendelian randomization studies, 34, 35 but an additional study suggested that the APOEE2 allele could increase gastric cancer risk, which might be associated with lower TC levels. 36 Additionally, undiagnosed liver disease apart from liver cancer may also affect the association between cholesterol and cancer, as we did not adjust serum ALT, AST and hepatitis B surface antigen in our study, which may also affect TC level and its relationship with cancer. Further, we did not explore the correlation between lipid profiles and cancer in females, although the Kailuan study included female subjects. In this Kailuan cohort study, we demonstrated that high level of TC, LDL-C or non-HDL-C is associated with ASCVD incidence in a male population. However, these lipid profiles are also negatively associated with the risk of all-site cancer and several individual cancers, and these associations with cancer risk cannot be entirely explained by the preclinical effects of cancer. Therefore, we believe that we should pay attention to the potential health risks linked to the use of cholesterol-lowering agents. More prospective studies and experimental data are needed to further confirm our findings, which may have important effects on public health, due to the fact that cholesterol-lowering has been crucial in cardiovascular disease prevention.
